Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer.
The effects of treatment with the aromatase inhibitors aminoglutethimide (AG) and formestane or the synthetic progestin megestrol acetate (MA) on plasma levels of insulin-like growth factor I (IGF-1), IGF-II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status were investigated in 39 patients suffering from advanced breast cancer. Treatment with AG and MA elevated plasma levels of IGF-I by mean values of 27% (n = 15; P < 0.025) and 81% (n = 7; P < 0.025), respectively, whereas treatment with formestane had no effect (n = 13). Treatment with AG increased plasma levels of IGFBP-2, as evaluated by Western blotting (P < 0.01). MA caused a significant reduction in IGFBP-3 protease activity (mean reduction, 69%; P < 0.05). These alterations in plasma IGF-I and IGFBP-3 protease activity were reversed 4 weeks after terminating MA therapy (n = 8; P < 0.025). Taken together, 13 of 15 patients had reduced IGFBP-3 protease activity during treatment with MA compared to the control situation (P < 0.0025). Total levels of IGFBP-3 as measured by RIA were moderately elevated by treatment with MA (mean increase, 19%; P < 0.05), and Western immunoblotting revealed an increase in the amount of intact IGFBP-3 and reduced amounts of IGFBP-3 in the modified form. None of the treatment modalities had any influence on plasma levels of IGF-II. The increase in the plasma IGF-I concentration seen during treatment with MA may be secondary to an increased level of intact IGFBP-3. This could reflect an alteration in IGF availability that contributes to the antitumor effect of MA.
Frost
V J
VJ
Department of Chemical Endocrinology, St. Bartholomew's Hospital, London, United Kingdom.
Helle
S I
SI
Lønning
P E
PE
van der Stappen
J W
JW
Holly
J M
JM
D000368:Aged; D000369:Aged, 80 and over; D000616:Aminoglutethimide / Q000627:therapeutic use; D000735:Androstenedione / Q000031:analogs & derivatives / Q000627:therapeutic use; D047072:Aromatase Inhibitors; D015153:Blotting, Western; D001943:Breast Neoplasms / Q000097:blood* / Q000188:drug therapy*; D010450:Endopeptidases / Q000097:blood*; D005260:Female; D006801:Humans; D018969:Insulin-Like Growth Factor Binding Proteins / Q000097:blood*; D019290:Megestrol Acetate / Q000627:therapeutic use; D008875:Middle Aged; D011863:Radioimmunoassay; D013002:Somatomedins / Q000378:metabolism*
D047072:Aromatase Inhibitors; D018969:Insulin-Like Growth Factor Binding Proteins; D013002:Somatomedins; D000616:Aminoglutethimide; D000735:Androstenedione; D010450:Endopeptidases; C080473:insulin-like growth factor binding protein-3 protease; C014594:formestane; D019290:Megestrol Acetate